PATH vs XBIO · P/E 19, rev $1.61B vs rev $2.5M
Uipath Inc (PATH) versus Xenetic Biosciences Inc (XBIO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Xenetic Biosciences Inc (XBIO) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported XBIO revenue for 2024-12-31 was $2.5M. Net income was -$4.0M. Revenue was down 1.6% from 2023-12-31 to 2024-12-31. XBIO currently screens at market cap $5.7M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. XBIO currently screens at market cap $5.7M.
Not investment advice. Open the PATH and XBIO stock pages for the full models.
Not investment advice.